Diffuse Large B-Cell Lymphoma News

News

Study Clarifies Superiority of High-Dose Methotrexate at EOI for High-Risk Patients With DLBCL

02/24/2022

A multicenter analysis has clarified the superiority of high-dose methotrexate at the EOI for high-risk patients with DLBCL.

A multicenter analysis has...

02/24/2022

Oncology

News

Post-ASCT Pembrolizumab Maintenance Associated With Elevated Circulating DCs for DLBCL

02/11/2022

Early features of post-ASCT immune reconstitution is associated with a persistent elevation of circulating DCs in patients with cHL and DLBCL.

Early features of post-ASCT...

02/11/2022

Oncology

News

Polatuzumab Vedotin Combo Shows Promising Activity in R/R DLBCL

02/04/2022

Polatuzumab vedotin has shown promising activity when combined with rituximab and bendamustine in patients with R/R DLBCL.

Polatuzumab vedotin has shown...

02/04/2022

Oncology

News

Comparing R-MiniCHOP With or Without Azacitidine in Patients With Lymphomas, Including DLBCL

01/10/2022

A randomized study of R-miniCHOP with or without oral azacitidine in patients with newly diagnosed DLBCL, grade 3B FL, transformed lymphoma, and high-grade B-cell lymphomas with MTC and BCL2 and/or BCL6 rearrangements, was presented at the...

A randomized study of R-miniCHOP...

01/10/2022

Oncology

News

Acalabrutinib Plus AZD9150 is Safe and Effective in Patients With R/R DLBCL

01/04/2022

Data of the combination of acalabrutinib and AZD9150 in patients with R/R DLBCL from a phase 1 study were presented at the 2021 ASH Annual Meeting.

Data of the combination of...

01/04/2022

Oncology

News

Phase 1b Trial Shows Safety of CD19-7x19 CAR-T Cells in Combination With Anti-PD-1 Antibody for R/R DLBCL

01/04/2022

Data of CD19-7x19 CAR-T cells plus anti-PD-1 antibody from a groundbreaking clinical trial were presented at the 2021 ASH Annual Meeting to highlight the safety and efficacy of this new strategy.

Data of CD19-7x19 CAR-T cells...

01/04/2022

Oncology

News

Extranodal Presentation is Not a Prognostic Marker in Limited Stage DLBCL

12/22/2021

Data analyses from the 3 sequential SWOG trials were presented at the 2021 ASH Annual Meeting to highlight extranodal presentation in limited stage DLBCL.

Data analyses from the 3...

12/22/2021

Oncology

News

Naratuximab Emtansine Plus Rituximab Shows Safety in Patients With DLBCL and Other B-NHLs

12/08/2021

A phase 2 study of naratuximab emtansine plus rituximab found it has promising safety and efficacy for patients with DLBCL and other B-NHLs; these data were presented at the 2021 Annual ASH Meeting.

A phase 2 study of naratuximab...

12/08/2021

Oncology

News

FDA Approves Rituximab Plus Chemo for Certain Pediatric Cancers

12/03/2021

On December 2, 2021, the FDA approved the combination of rituximab plus chemotherapy for previously untreated pediatric patients with advanced stage CD20+ DLBCL, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

On December 2, 2021, the FDA...

12/03/2021

Oncology

News

Tafasitamab Associated With Meaningful, Well-Defined, Long-Term Outcomes in R/R DLBCL

12/02/2021

An updated analysis of the phase 2 L-MIND trial showed tafasitamab had meaningful OS and a well-defined safety profile in patients with R/R DLBCL.

An updated analysis of the phase...

12/02/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology